Search

Your search keyword '"Muda AO"' showing total 7 results
Start Over Author "Muda AO" Database OpenAIRE
7 results on '"Muda AO"'

6. PML down-regulation in soft tissue sarcomas

Author

Sabrina Rossi, Andrea Onetti Muda, Marianna Silletta, Nicola Gebbia, Federica Grosso, Giuseppe Perrone, Daniele Santini, A.M. Frezza, Angelo Paolo Dei Tos, Antonio Russo, Giuseppe Badalamenti, Carla Rabitti, Giuseppe Tonini, Bruno Vincenzi, Paolo G. Casali, Vincenzi, B, Perrone, G, Santini, D, Grosso, F, Silletta, M, Frezza, A, Rossi, S, Russo, A, Rabitti, C, Gebbia, N, Badalamenti, G, Casali, P, Muda, AO, Dei tos, AP, Tonini, G, and Vincenzi B, Perrone G, Santini D, Grosso F, Silletta M, Frezza A, Rossi S, Russo A, Rabitti C, Gebbia N, Badalamenti G, Casali P, Muda AO, Dei Tos AP, Tonini G.

Subjects
Leiomyosarcoma, Pathology, medicine.medical_specialty, Physiology, soft tissue tumor, Settore MED/06 - Oncologia Medica, Clinical Biochemistry, Down-Regulation, Liposarcoma, Promyelocytic Leukemia Protein, Pleomorphic Liposarcoma, PML, sarcomas, Promyelocytic leukemia protein, medicine, Humans, sarcomas, neoplasms, Myxoid liposarcoma, PML, biology, business.industry, Soft tissue sarcoma, Tumor Suppressor Proteins, Nuclear Proteins, Sarcoma, Cell Biology, Anatomy, medicine.disease, Immunohistochemistry, Synovial sarcoma, body regions, biology.protein, business, Transcription Factors
Abstract

To date, little is known concerning the promyelocytic leukemia gene (PML) status in tumors of different origin, and its expression has never been evaluated in soft tissue sarcoma. The aim of the present study is focused on the identification of differences in terms of PML protein expression between different types of soft tissue sarcoma and the corresponding normal surrounding tissue. PML protein expression has been assessed by immunohistochemistry in six different histologic types of soft tissue sarcoma (synovial sarcoma, myofibroblastic sarcoma, angiosarcoma, liposarcoma, pleomorphic sarcoma, and leiomyosarcoma) and in the corresponding normal surrounding tissue. PML resulted significantly down-regulated in synovial sarcoma and in myofibroblastic sarcoma specimens. Also in angiosarcoma samples a significative difference in PML expression in comparison with normal specimens has been detected. Interestingly PML protein detection showed a different pattern of expression in the three liposarcoma histology types compared with corresponding nontumoral tissues. In particular PML protein resulted significantly down-regulated in myxoid liposarcoma and in dedifferentiated liposarcoma. On the contrary no statistically significant difference was observed in pleomorphic liposarcoma compared to normal tissue specimens. Further investigations are needed to confirm these data and to assess the possible value of PML expression as a prognostic factor in these extremely aggressive diseases.

Published
2010

7. PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients

Author

Fotios Loupakis, Alfredo Falcone, Sergio Rizzo, Gaia Schiavon, Carla Rabitti, Pierfilippo Crucitti, Daniele Santini, Annamaria Ruzzo, Giuseppe Tonini, Giuseppe Perrone, Bruno Vincenzi, Anna Maria Frezza, Francesco Graziano, Antonio Russo, Andrea Onetti Muda, Alice Zoccoli, Sara Galluzzo, Vincenzi B, Santini D, Perrone G, Graziano F, Loupakis, F, Schiavon, G, Frezza, AM, Ruzzo, AM, Rizzo, S, Crucitti, P, Galluzzo, S, Zoccoli, A, Rabitti, C, Muda, AO, Russo, A, Falcone, A, and Tonini, G

Subjects
Oncology, Male, Organoplatinum Compounds, Oxaloacetates, Physiology, Colorectal cancer, Settore MED/06 - Oncologia Medica, viruses, Clinical Biochemistry, Cell, Leucovorin, Promyelocytic Leukemia Protein, medicine.disease_cause, Deoxycytidine, Antineoplastic Combined Chemotherapy Protocols, biology, virus diseases, Nuclear Proteins, Middle Aged, Oxaliplatin, Survival Rate, medicine.anatomical_structure, Immunohistochemistry, oxaliplatin/fluoropyrimidine, Female, Fluorouracil, Colorectal Neoplasms, medicine.drug, Adult, medicine.medical_specialty, Antimetabolites, Antineoplastic, PML, colorectal cancer, Antineoplastic Agents, Promyelocytic leukemia protein, Predictive Value of Tests, Internal medicine, medicine, Humans, Capecitabine, Aged, Retrospective Studies, business.industry, Tumor Suppressor Proteins, Retrospective cohort study, Cell Biology, medicine.disease, Apoptosis, Drug Resistance, Neoplasm, biology.protein, Carcinogenesis, business, Transcription Factors
Abstract

PML regulates a wide range of pathways involved in tumorigenesis, such as apoptosis, which is also one of the main mechanisms through which oxaliplatin and fluoropyrimidine exert their antineoplastic activity. The present study aims to investigate PML expression as a predictive factor of oxaliplatin/fluoropyrimidine therapy efficacy. Seventy-four metastatic colorectal cancer patients who received oxaliplatin/floropyrimidine-based first line therapy have been included in this retrospective study. PML expression was assessed by immunohistochemistry. PML down-regulation was detected in 39 (52.7%) patients (14 complete and 25 partial PML loss). RR was significantly lower (25.6%) in patients with PML down-regulation than in patients with preserved PML expression (60%) (P = 0.006). Median TTP was 5.5 months when PML was down-regulated versus 11.9 months in case of preserved PML expression (P

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results